Almac is proud to support multiple programs to accelerate COVID-19 treatment
Almac is proud to support multiple programs to accelerate COVID-19 treatment
Almac is proud to support over 140 separate crucial research programs to accelerate COVID-19 treatment
We are proud that Almac is continuing to play our part in the fight against the COVID-19 pandemic.
We are continuing to partner with a variety of global pharmaceutical, biotech and research institutions to support over 140 separate crucial research projects into COVID-19 treatment options. In addition, we are currently in discussions with clients on how we can support an additional 60 programmes.
We are supporting this urgent research need through a range of service areas, including analytical services, peptide development, expedited Interactive Response Technology (IRT) support and clinical trial manufacturing, packaging and distribution.
These vital projects cover a range of different areas including vaccines and various potential treatments for symptoms and the effects of this disease.
In addition to this immediate research support, Almac continues to directly contribute to key operations in the supply chain of hundreds of life-saving drugs in a wide variety of therapeutic areas including oncology, neurology, pain management and cardiovascular.
Almac continues to conduct critical business operations and our dedicated, skilled employees will continue to support these critical supply chains.
To find out more about how Almac can support your project please contact us and we will be happy to discuss your specific requirements.
Latest news and resources
Supporting multiple programs through a range of service areas
Accelerating study start up with Simplify™ IRT
Leveraging the power of the industry’s leading IRT offering flexibility without delay, the Almac Simplify team devoted themselves day and night to get a system up and running, and ready to randomise the first patient in just six days.
Learn more
Accelerating study start up with Simplify™ IRT“>
Crucial Peptide expertise
From Almac’s high-throughput GMP manufacturing facility, the peptide team focused on the rapid manufacture of peptide-based COVID-19 vaccine candidates and the manufacture of peptide-based therapeutics repurposed for potential COVID-19 treatments.
Learn more
Crucial Peptide expertise“>
Direct to Patient Via Site
With increasing numbers of patients unable to travel to sites due to Government restrictions on movements, Almac is facilitating site to patient deliveries globally.
Learn more
Direct to Patient Via Site“>
Almac to Patient
When sites are closed, or key staff aren’t able to travel to a site due to an increase in restrictions and lockdowns, Almac ships supplies directly to the patient’s home from an Almac facility, all whilst upholding GXP compliance.
Learn more
Almac to Patient “>
Just in Time Manufacturing
Flexible solutions such as full late-stage customisation of clinical supplies by postponing packaging and labelling until the site or patient need arises.
Learn more
Just in Time Manufacturing “>
Next Generation Temperature Management
As Almac understands your temperature control challenges, our experts use an end to end regulatory compliant solution that gives full visibility of your temperature data from any stakeholder within your supply chain.
Learn more
Next Generation Temperature Management“>
Almac ONE™
A unified clinical trial solution that integrates patient recruitment, clinical supply and Interactive Response Technology (IRT) strategies with closed-loop technology to enable a holistic data flow that leverages insights to give you greater flexibility and visibility over your clinical supply.
Learn more
Almac ONE™“>